Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $13
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $11 to $13.
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $11 to $13.